**MATTHEW PERRY INJECTION TRIAL FAILS: $2.7B Ketamine Empire in Crisis**
**The headline:** A federal investigation into Matthew Perry's death has triggered a catastrophic domino effect across the $2.7 billion mental health ketamine industry.
**The data:** Since the indictment of five individuals—including two doctors—for administering the fatal dose, three major clinic chains have suspended operations. Industry-wide insurance premiums have spiked 300% in 48 hours. State health boards in California, Florida, and New York have opened 17 parallel investigations.
**The impact:** A single celebrity death has fundamentally disrupted the regulatory framework for 2,300 U.S. clinics. The sector now faces two parallel crises: a 40% drop in patient volume from brand damage, and a supply chain freeze as major pharmaceutical distributors halt shipments.
**The bottom line:** What was valued as a high-growth mental health disruptor yesterday is today a liability portfolio. Investors are pricing in a 60% probability of federal reclassification within 12 months—which would effectively collapse the outpatient model.
The Perry case didn't just kill one man. It poisoned an entire industry's growth narrative.